Blogs

Categories

Select a Sub-Category

Films and Coatings
Pharmaceutical Packaging Components
Prefillable Systems
Self Injection Devices
Vial Containment Solutions
Washing and Sterilization
Reconstitution and Transfer Devices

Select a Sub-Category

Analytical Lab Services
Contract Manufacturing
Fill-Finish
Regulatory Support

Select a Sub-Category

Cell and Gene Therapy Packaging
Drug Development Process
Regulatory Challenges
Transitioning to Combination Products

Select a Sub-Category

Corporate Development
ESG/Sustainability
One West Team (Employee Culture)
Our Culture of Giving (Philanthropy)
Research and Development

Previous Blogs

By Gabrielle Gehron

三月 13, 2020

Historically, finding suitable containers for complex protein drug products has been difficult, since interaction with elastomeric closures can result in particle formation. These particles indicate an underlying change within the drug product, undermining integrity and risking patient safety. The correlation of silicone coatings with protein aggregation has made some wary of their use; however, an elastomeric closure with no coating or film can be difficult to process. Another concern is that leachables originating from the elastomeric closure can induce particle formation.